We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+51.49%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$1.14B
AUM Growth
+$289M
Cap. Flow
+$29.7M
Cap. Flow %
2.6%
Top 10 Hldgs %
62.98%
Holding
38
New
8
Increased
7
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$31.1M
2
SYRE icon
Spyre Therapeutics
SYRE
+$24.4M
3
ARVN icon
Arvinas
ARVN
+$23.4M
4
ABVX
Abivax
ABVX
+$19.3M
5
PHVS icon
Pharvaris
PHVS
+$16.2M

Top Sells

Rank Stock Value
1
AMAM
Ambrx Biopharma Inc
AMAM
+$40.5M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$20.9M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$16.6M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$14.9M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$131M 11.41%
4,747,373
+319,301
+7% +$7.46M
XENE icon
2
Xenon Pharmaceuticals
XENE
$6.32B
$99.8M 8.72%
2,167,793
+322,793
+17% +$11.4M
NUVL
3
DELISTED
Nuvalent
NUVL
$98M 8.56%
1,331,037
+502,259
+61% +$31.1M
VERA icon
4
Vera Therapeutics
VERA
$2.54B
$83.8M 7.32%
5,450,000
– –
RYTM icon
5
Rhythm Pharmaceuticals
RYTM
$7B
$71.3M 6.23%
1,550,000
-525,000
-25% -$16.6M
PCVX icon
6
Vaxcyte
PCVX
$7.89B
$69.1M 6.04%
1,100,000
– –
CABA icon
7
Cabaletta Bio
CABA
$439M
$43.1M 3.77%
1,900,000
-625,753
-25% -$10.5M
IMVT icon
8
Immunovant
IMVT
$8.09B
$42.1M 3.68%
1,000,000
– –
VRDN icon
9
Viridian Therapeutics
VRDN
$2.13B
$41.9M 3.66%
1,924,074
-275,926
-13% -$4.36M
ARVN icon
10
Arvinas
ARVN
$518M
$41.2M 3.6%
+1,000,000
New +$23.4M
SYRE icon
11
Spyre Therapeutics
SYRE
$8.87B
$40.5M 3.54%
1,884,084
+1,767,760
+1,520% +$24.4M
ELVN icon
12
Enliven Therapeutics
ELVN
$3.78B
$40.2M 3.51%
2,901,816
– –
COGT icon
13
Cogent Biosciences
COGT
$6.79B
$32.7M 2.86%
5,566,026
– –
ALPN
14
DELISTED
Alpine Immune Sciences Inc
ALPN
$30.7M 2.68%
1,610,000
+285,000
+22% +$3.96M
SLNO
15
DELISTED
Soleno Therapeutics
SLNO
$28.2M 2.46%
700,000
-187,500
-21% -$5.33M
CLDX icon
16
Celldex Therapeutics
CLDX
$2.77B
$27.8M 2.43%
701,967
-4,698
-0.7% -$138K
CELC icon
17
Celcuity
CELC
$4.03B
$25.6M 2.23%
1,754,704
+60,563
+4% +$731K
RYZB
18
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$23.9M 2.08%
383,638
+94,727
+33% +$2.35M
PHVS icon
19
Pharvaris
PHVS
$2.39B
$22.4M 1.96%
+800,000
New +$16.2M
CCCC icon
20
C4 Therapeutics
CCCC
$376M
$21.5M 1.88%
+3,800,000
New +$8.66M
ABVX
21
Abivax
ABVX
$11B
$20.3M 1.77%
+1,895,003
New +$19.3M
NKTX icon
22
Nkarta
NKTX
$162M
$18M 1.57%
+2,730,000
New +$7.07M
KURA icon
23
Kura Oncology
KURA
$922M
$17.9M 1.57%
1,248,062
-151,938
-11% -$1.49M
HARP
24
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$17.1M 1.49%
+1,500,000
New +$11.8M
AKRO
25
DELISTED
Akero Therapeutics
AKRO
$13.2M 1.15%
565,000
– –
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Commodore Capital held 38 positions worth $1.14B, up 34% from $856M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Commodore Capital's Q4 2023 filing shows 8 new, 7 increased, 7 reduced and 6 closed positions. Its largest new stake was Arvinas: 1,000,000 shares worth $41.2M. The largest sale was Ambrx Biopharma Inc, an estimated $40.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Commodore Capital's largest Q4 2023 buy was Arvinas: 1,000,000 shares worth $41.2M.
  • Commodore Capital added most to Nuvalent in Q4 2023, an estimated $31.1M increase.
  • Commodore Capital's biggest Q4 2023 reduction was Rhythm Pharmaceuticals, cutting an estimated $16.6M.
  • Commodore Capital fully exited Ambrx Biopharma Inc in Q4 2023, selling an estimated $40.5M.
  • Commodore Capital's ten largest holdings make up 63% of its $1.14B portfolio in Q4 2023.
  • Commodore Capital opened 8 new positions and closed 6 in Q4 2023.
  • Commodore Capital's portfolio value rose 34% quarter-over-quarter to $1.14B.

Based on Commodore Capital's 13F filing for Q4 2023, filed 14 Feb 2024.